scholarly journals Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias

2016 ◽  
Vol 194 (10) ◽  
pp. 1242-1251 ◽  
Author(s):  
Eric S. White ◽  
Meng Xia ◽  
Susan Murray ◽  
Rachel Dyal ◽  
Candace M. Flaherty ◽  
...  
2017 ◽  
Vol 131 ◽  
pp. 184-191 ◽  
Author(s):  
Kimiyuki Ikeda ◽  
Masanori Shiratori ◽  
Hirofumi Chiba ◽  
Hirotaka Nishikiori ◽  
Keiki Yokoo ◽  
...  

2012 ◽  
Vol 302 (8) ◽  
pp. L746-L754 ◽  
Author(s):  
Thomas J. Richards ◽  
Chunghyun Park ◽  
Yiliang Chen ◽  
Kevin F. Gibson ◽  
Y. Peter Di ◽  
...  

Idiopathic pulmonary fibrosis (IPF) is a complex disease with poorly understood etiology. Previously, we reported upregulation of matrix metalloproteinase 7 (MMP7) in both lung and peripheral blood of IPF patients. Here we report evidence for genetic correlation of plasma levels and promoter polymorphisms (rs11568818 and rs11568819) of MMP7 in a well-characterized IPF cohort. Both the AA genotype of rs11568818 and the CT genotype of rs11568819 were found to be significantly associated with higher MMP7 plasma levels. These associations were observed only in IPF patients and not in healthy controls. The G-to-A transition of rs11568818 resulted in a novel binding site for the forkhead box A2 (FOXA2) transcription factor, a key regulator of embryonic lung development and proper function of the mature lung. In vitro, this transition led to increased sensitivity of the MMP7 promoter to FOXA2. In IPF lungs, FOXA2 was localized in the nucleus of epithelial cells that expressed MMP7 in the cytoplasm. These results suggest that increased sensitivity of the polymorphic MMP7 promoter to FOXA2 provides one of the genetic bases for the upregulation of MMP7 in IPF.


CHEST Journal ◽  
2011 ◽  
Vol 140 (2) ◽  
pp. 489-496 ◽  
Author(s):  
Michael W. Sims ◽  
Michael F. Beers ◽  
Vivek N. Ahya ◽  
Steven M. Kawut ◽  
Karen D. Sims ◽  
...  

2019 ◽  
Vol 13 (2) ◽  
pp. 214 ◽  
Author(s):  
YasmineH El Hinnawy ◽  
MohamedA El Nady ◽  
SafyZ Kaddah ◽  
Radwa M.A Halim ◽  
RehamH Kandeel

2017 ◽  
Vol 3 (3) ◽  
pp. 00019-2016 ◽  
Author(s):  
Akihiko Sokai ◽  
Kiminobu Tanizawa ◽  
Tomohiro Handa ◽  
Kumiko Kanatani ◽  
Takeshi Kubo ◽  
...  

The clinical significance of serial changes in serum biomarkers in patients with idiopathic pulmonary fibrosis (IPF) remains to be established. This retrospective study was conducted to clarify the associations of serial changes in serum Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) with changes in physiological indices and overall mortality in IPF.The study subjects were 75 patients with IPF. The 6 month change in serum KL-6 was significantly correlated with changes in the percentage of the predicted forced vital capacity (FVC % pred) and the percentage of the predicted diffusing capacity of the lung for carbon monoxide (% DLCO), while the 6 month change in serum SP-D was correlated only with % DLCO. During the mean follow-up period of 647 days, 22 (29.3%) patients died. An increase in serum KL-6 over a 6 month period was a significant predictor of mortality even after adjustment for %FVC, % DLCO and serum KL-6 at the baseline (hazard ratio 1.10 per 100 U·mL−1, 95% CI 1.01–1.18, p=0.03), whereas the 6 month increase in serum SP-D was not significant.Serial measurements of serum KL-6 may provide additional prognostic information compared to that provided by physiological parameters in patients with IPF.


Sign in / Sign up

Export Citation Format

Share Document